File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
  • Basic View
  • Metadata View
  • XML View
TitleAn H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
 
AuthorsZhao, G1
Sun, S1
Du, L4
Xiao, W1
Ru, Z1 3
Kou, Z1
Guo, Y1
Yu, H1
Jiang, S4
Lone, Y3
Zheng, BJ2
Zhou, Y1
 
Issue Date2010
 
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.virologyj.com/home/
 
CitationVirology Journal, 2010, v. 7 [How to Cite?]
DOI: http://dx.doi.org/10.1186/1743-422X-7-151
 
AbstractBackground. A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus. Results. Our results demonstrated that H5N1-M2e-MAP plus Freund's or aluminum adjuvant induced strong cross-reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus, showing significant decrease of viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100% and 80% of the H5N1-M2e-MAP-vaccinated mice with Freund's and aluminum adjuvant, respectively, survived the lethal challenge with pandemic H1N1 virus. Conclusions. Our results suggest that H5N1-M2e-MAP has a great potential to prevent the threat from re-emergence of pandemic H1N1 influenza and possible novel influenza pandemic due to the reassortment of HPAI H5N1 virus with the 2009 swine-origin H1N1 influenza virus. © 2010 Zhao et al; licensee BioMed Central Ltd.
 
ISSN1743-422X
2013 Impact Factor: 2.089
2013 SCImago Journal Rankings: 1.023
 
DOIhttp://dx.doi.org/10.1186/1743-422X-7-151
 
PubMed Central IDPMC2912260
 
ISI Accession Number IDWOS:000282601300001
Funding AgencyGrant Number
Natural Science Foundation of China30901371
Mega-projects of Science Research for the 11th Five-Year Plan2009ZX10004-401
National Basic Research Program of China (973 Program)2005CB523001
National Science and Technology Infrastructure Program2006BA06A15
Funding Information:

This study was supported by Natural Science Foundation of China (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-401), National Basic Research Program of China (973 Program, 2005CB523001), and National Science and Technology Infrastructure Program (2006BA06A15).

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorZhao, G
 
dc.contributor.authorSun, S
 
dc.contributor.authorDu, L
 
dc.contributor.authorXiao, W
 
dc.contributor.authorRu, Z
 
dc.contributor.authorKou, Z
 
dc.contributor.authorGuo, Y
 
dc.contributor.authorYu, H
 
dc.contributor.authorJiang, S
 
dc.contributor.authorLone, Y
 
dc.contributor.authorZheng, BJ
 
dc.contributor.authorZhou, Y
 
dc.date.accessioned2011-07-27T01:31:05Z
 
dc.date.available2011-07-27T01:31:05Z
 
dc.date.issued2010
 
dc.description.abstractBackground. A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus. Results. Our results demonstrated that H5N1-M2e-MAP plus Freund's or aluminum adjuvant induced strong cross-reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus, showing significant decrease of viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100% and 80% of the H5N1-M2e-MAP-vaccinated mice with Freund's and aluminum adjuvant, respectively, survived the lethal challenge with pandemic H1N1 virus. Conclusions. Our results suggest that H5N1-M2e-MAP has a great potential to prevent the threat from re-emergence of pandemic H1N1 influenza and possible novel influenza pandemic due to the reassortment of HPAI H5N1 virus with the 2009 swine-origin H1N1 influenza virus. © 2010 Zhao et al; licensee BioMed Central Ltd.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationVirology Journal, 2010, v. 7 [How to Cite?]
DOI: http://dx.doi.org/10.1186/1743-422X-7-151
 
dc.identifier.citeulike7493888
 
dc.identifier.doihttp://dx.doi.org/10.1186/1743-422X-7-151
 
dc.identifier.hkuros188635
 
dc.identifier.isiWOS:000282601300001
Funding AgencyGrant Number
Natural Science Foundation of China30901371
Mega-projects of Science Research for the 11th Five-Year Plan2009ZX10004-401
National Basic Research Program of China (973 Program)2005CB523001
National Science and Technology Infrastructure Program2006BA06A15
Funding Information:

This study was supported by Natural Science Foundation of China (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-401), National Basic Research Program of China (973 Program, 2005CB523001), and National Science and Technology Infrastructure Program (2006BA06A15).

 
dc.identifier.issn1743-422X
2013 Impact Factor: 2.089
2013 SCImago Journal Rankings: 1.023
 
dc.identifier.pmcidPMC2912260
 
dc.identifier.pmid20624292
 
dc.identifier.scopuseid_2-s2.0-77954409486
 
dc.identifier.urihttp://hdl.handle.net/10722/135277
 
dc.identifier.volume7
 
dc.languageeng
 
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.virologyj.com/home/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofVirology Journal
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.rightsVirology Journal. Copyright © BioMed Central Ltd.
 
dc.subject.meshCross Protection
 
dc.subject.meshDisease Outbreaks
 
dc.subject.meshInfluenza Vaccines - administration and dosage - immunology
 
dc.subject.meshInfluenza, Human - epidemiology - immunology - prevention and control - virology
 
dc.subject.meshViral Matrix Proteins - administration and dosage - chemistry - immunology
 
dc.titleAn H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Zhao, G</contributor.author>
<contributor.author>Sun, S</contributor.author>
<contributor.author>Du, L</contributor.author>
<contributor.author>Xiao, W</contributor.author>
<contributor.author>Ru, Z</contributor.author>
<contributor.author>Kou, Z</contributor.author>
<contributor.author>Guo, Y</contributor.author>
<contributor.author>Yu, H</contributor.author>
<contributor.author>Jiang, S</contributor.author>
<contributor.author>Lone, Y</contributor.author>
<contributor.author>Zheng, BJ</contributor.author>
<contributor.author>Zhou, Y</contributor.author>
<date.accessioned>2011-07-27T01:31:05Z</date.accessioned>
<date.available>2011-07-27T01:31:05Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Virology Journal, 2010, v. 7</identifier.citation>
<identifier.issn>1743-422X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/135277</identifier.uri>
<description.abstract>Background. A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus. Results. Our results demonstrated that H5N1-M2e-MAP plus Freund&apos;s or aluminum adjuvant induced strong cross-reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus, showing significant decrease of viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100% and 80% of the H5N1-M2e-MAP-vaccinated mice with Freund&apos;s and aluminum adjuvant, respectively, survived the lethal challenge with pandemic H1N1 virus. Conclusions. Our results suggest that H5N1-M2e-MAP has a great potential to prevent the threat from re-emergence of pandemic H1N1 influenza and possible novel influenza pandemic due to the reassortment of HPAI H5N1 virus with the 2009 swine-origin H1N1 influenza virus. &#169; 2010 Zhao et al; licensee BioMed Central Ltd.</description.abstract>
<language>eng</language>
<publisher>BioMed Central Ltd. The Journal&apos;s web site is located at http://www.virologyj.com/home/</publisher>
<relation.ispartof>Virology Journal</relation.ispartof>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<rights>Virology Journal. Copyright &#169; BioMed Central Ltd.</rights>
<subject.mesh>Cross Protection</subject.mesh>
<subject.mesh>Disease Outbreaks</subject.mesh>
<subject.mesh>Influenza Vaccines - administration and dosage - immunology</subject.mesh>
<subject.mesh>Influenza, Human - epidemiology - immunology - prevention and control - virology</subject.mesh>
<subject.mesh>Viral Matrix Proteins - administration and dosage - chemistry - immunology</subject.mesh>
<title>An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus</title>
<type>Article</type>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1186/1743-422X-7-151</identifier.doi>
<identifier.pmid>20624292</identifier.pmid>
<identifier.pmcid>PMC2912260</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-77954409486</identifier.scopus>
<identifier.hkuros>188635</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77954409486&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>7</identifier.volume>
<identifier.isi>WOS:000282601300001</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>7493888</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/135277/1/1743-422X-7-151.pdf</bitstream.url>
</item>
Author Affiliations
  1. Institute of Microbiology Chinese Academy of Sciences
  2. The University of Hong Kong
  3. Universite Paris-Sud XI
  4. New York Blood Center